Business Standard

Divi's Labs gains 5% as USFDA issues no observations for Telangana plant

The Company's Unit-I facility at Lingojigudem, Bhuvanagiri Yadadri district, Telangana has been inspected by the USFDA from the November 11, to November 15, 2019.

Pharma
Premium

SI Reporter Mumbai
Shares of Divi's Laboratories climbed 5 per cent to Rs 1,736 in the intra-day trade on the BSE on Friday after the company announced that the US health regulator FDA issued no 483 observations for its Unit-1 facility in Telangana. The stock of the drug maker was trading close to its 52-week high price of Rs 1,776, touched on October 27, 2019.

“The Company's Unit-I facility at Lingojigudem, Bhuvanagiri Yadadri district, Telangana has been inspected by the US Food and Drug Administration (USFDA) from the 11th of November, 2019 to the 15th of November, 2019. The inspection has been

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in